Live Cell Encapsulation Market is expected to grow with an impressive CAGR in the forecast period of 2024-2028. This can be attributed to factors such as growing research & development in improving the effectiveness of cell encapsulation technologies, along with the rise in governmental and private investments supporting live cell encapsulated product development.
Live cell encapsulation is a bioengineering technology which includes encasing living cell with a material or coating. A distinct variety of materials are used for the encapsulation such as liposomes, hydrogels, and microcapsules.
Moreover, live cell encapsulation is found to have significant importance in cell therapies as it allows a controlled release of bioactive material or cells, and thereby is anticipated to bolster the market growth with rise in cell therapies across the globe.
Increase in Cell Therapies
The live cell encapsulation delivers the medicinal cell component or bioactive materials in a controlled manner and thus is efficient to be used in cell therapies as they include the delivery of therapeutics directly in the targeted location in the body. Additionally, they do not create any response by the body’s immune system and thus aren’t attacked or eliminated by the immune system. The encapsulates cells in cases carry out specific functions such as activating cancer drugs. For instance, in 2021, a company Nuvilex performed a research study in which the live cells were encapsulated within beads to treat pancreatic cancer. It was observed the cells converted the inactive cancer drug ifosfamide into its cancer-killing form and this specific property ensures the delivery of the chemotherapeutic drug directly to the tumor and thereby is found to have potential usage in the future.
Rising Prevalence of Chronic Disease
According to the report by the International Diabetes Foundation, in 2021 round 537 million adults were affected by diabetes, and it is expected to increase to 643 million by 2030, and by 2045, it will reach 783 million
Growing Research & Development to Improve Product Efficacy
Growing expansion of biotechnology with increasing research & development and rising company investments in live cell encapsulation technologies is leading to improvement in the development and clinical efficacy of live cell encapsulation. The growing investment and increased mutual associations to enhance the live cell encapsulation technological application and production by the key market players is further contributing to the growth of global live cell encapsulation market. For instance, In November 2022, a leading supplier of biocompatible materials- BIO INX collaborated with Nanoscribe- a microfabrication technology leader and launched HYDROBIO INX N400- that enables cell encapsulation in high resolution i.e., 3D printing and is especially designed for 3D microfabrication. Additionally, in July 2021, a clinical biotechnology company -PharmaCyte Biotech developed targeted treatments for cancer and diabetes using live-cell encapsulation technique and has commenced the first phase of a two-phase pig study used for investigating live cell encapsulation technology for diabetes treatment. Thus, growing research are providing opportunities for the companies to enhance the live cell encapsulation technique.
Market Segmentation
Global Live Cell Encapsulation Market is segmented based on polymer type, application, technique, region and competitive landscape. Based on polymer type, the market is segmented into alginate, chitosan, cellulose sulfate, and others. Based on application, the market is segmented into drug delivery, regenerative medicine, cell transplantation and probiotics. Based on technique, the market is segmented into simple dripping, electrostatic dripping, and coaxial airflow. Based on the region, the market is further segmented into North America, Europe, Asia-Pacific, South America, and MEA.
Market Players
AUSTRIANOVA, Merck KGaA, Sphere Fluidics Ltd., ViaCyte, Inc., Blacktrace Holdings Ltd. (Dolomite Microfluidics), BIO INX, Living Cell Technologies Ltd., Sigilon Therapeutics, Inc.,Isogen, Diatranz Otsuka Ltd.
Attribute | Details |
Base Year | 2022 |
Historical Years | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered | Polymer Type Application Technique |
Regional Scope | North America; Asia Pacific; Europe; South America; Middle East & Africa |
Country Scope | United States; Canada; Mexico; China; India; Japan; South Korea; Australia; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; Saudi Arabia; UAE; South Africa; Kuwait |
Key Companies Profiled | AUSTRIANOVA, Merck KGaA, Sphere Fluidics Ltd., ViaCyte, Inc., Blacktrace Holdings Ltd. (Dolomite Microfluidics), BIO INX, Living Cell Technologies Ltd., Sigilon Therapeutics, Inc.,Isogen, Diatranz Otsuka Ltd. |
Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |